Zykadia (ceritinib)

May 30, 2017

FDA Gives Green Light to Zykadia as First-line Therapy for ALK-positive NSCLC

News

The U.S. Food and Drug Administration has approved Norvartis‘ Zykadia (ceritinib) to be used as first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic ... Read more

November 1, 2016

Ariad’s New Drug Application of Brigatinib for NSCLC to Be Reviewed by FDA

News

The U.S. Food and Drug Administration (FDA) will review Ariad‘s new drug application (NDA) for brigatinib, an investigational therapy for patients with non-small cell lung cancer (NSCLC) who have progressed following ... Read more

October 18, 2016

Zykadia Better than Chemo as Second-line Treatment of Specific Lung Cancer, Trial Finds

News

Patients with non-small cell lung cancer (NSCLC) who have an ALK gene rearrangement and who were previously treated with the ALK inhibitor Xalkori (crizotinib) may strongly benefit from treatment with another ... Read more